NCT06607692 (LUPARPED) is a Phase 1/Phase 2 clinical trial of Olaparib; 177Lu-DOTATATE in Solid Tumor Cancer, sponsored by Fundación de investigación HM.

Who is sponsoring NCT06607692?

NCT06607692 is sponsored by Fundación de investigación HM.

What drugs are being tested in NCT06607692?

Interventions in NCT06607692: Olaparib; 177Lu-DOTATATE.

What condition does NCT06607692 study?

NCT06607692 studies Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumours (NET), Adrenal Tumours, DIPG, Glioblastoma, Glioblastoma (GBM), Osteosarcoma Recurrent, Carcinoma Adrenal, Synovial Sarcomas, Esthesioneuroblastoma, Neuroblastoma Recurrent, Solid Tumor Refractory to Conventional Treatment, Medulloblastoma Recurrent, Paraganglioma/ Phaeochromocytoma, Ependymoma, Ependymoma Recurrent.

Is NCT06607692 still recruiting?

NCT06607692 is currently recruiting now. Last updated 2 June 2026.

Last reviewed 2026-06-02 · How we verify

NCT06607692: LUPARPED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Recruiting now Phase 1/Phase 2 Last updated 2 June 2026

What this trial tests

Phase 1/Phase 2 trial testing Olaparib; 177Lu-DOTATATE in Solid Tumor Cancer in 25 participants. Currently enrolling.

Timeline

20 September 2024

Primary endpoint
1 July 2029

1 December 2029

Quick facts

Lead sponsor	Fundación de investigación HM
Phase	Phase 1/Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	20 September 2024
Primary completion	1 July 2029
Estimated completion	1 December 2029
Sites	1 location across Spain

Drugs / interventions tested

Olaparib; 177Lu-DOTATATE — full drug profile →

Conditions studied

Solid Tumor Cancer — all drugs for Solid Tumor Cancer →
Medulloblastoma — all drugs for Medulloblastoma →
High Risk Neuroblastoma — all drugs for High Risk Neuroblastoma →
High Grade Gliomas — all drugs for High Grade Gliomas →

Sponsor

Fundación de investigación HM — full company profile →

Who can join

3 and older, any sex, with Solid Tumor Cancer or Medulloblastoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To estimate the safety of the combination of 177LUDOTATATE and olaparib.
Time frame: Through first cycle, an average of 8 weeks
Measured by incidence of DLTs; finding of MTD and RP2D
To estimate the preliminary activity of the combination of 177LUDOTATATE and olaparib.
Time frame: From enrollment to the end of treatment, up to 24 months
ORR

Sponsor's own description

Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.
Virgolini IJ, Di Santo G, Santo G. · · 2026 · cited 2× · PMID 41689648 · DOI 10.1007/s00259-025-07750-w
Medulloblastoma: Current Standard of Care and Future Treatment Opportunities.
Mayr L, Azizi AA, Gojo J, Peyrl A. · · 2026 · cited 1× · PMID 41120656 · DOI 10.1007/s40272-025-00726-1
Atypical R-loops in cancer: decoding molecular chaos for therapeutic gain.
Sun Y, Wang S, Ge N, Guo J, et al · · 2025 · cited 1× · PMID 40813661 · DOI 10.1186/s12967-025-06929-x
Treating Pediatric Oncology Patients: The Emerging Role of Radioligand Therapy.
Laetsch TW, States LJ, Lazow MA, Chauhan A. · · 2025 · PMID 41375023 · DOI 10.3390/cancers17233821

Verify or expand the search:

Other recruiting trials for Solid Tumor Cancer

Currently open trials in the same condition.

NCT06802172 — Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial · NA · recruiting
NCT07441174 — IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Soli · Phase 1, PHASE2 · recruiting
NCT07218874 — Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application · NA · recruiting
NCT07269899 — A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT07146672 — Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors · Phase 1, PHASE2 · recruiting

Other Fundación de investigación HM trials

Trials by the same sponsor.

NCT05914051 — PRELOAD-TAVI Trial · NA · unknown
NCT06840678 — Home-based Transcranial Static Magnetic Field Stimulation (tSMS) of the Supplementary Motor Area in Parkinson's Disease · Phase 1 · recruiting
NCT05513755 — Cardioneuroablation in Reflex Syncope (CARDIOSYRE Trial) · NA · unknown
NCT04692116 — Parkinson's Disease (PD) Treated With Focused Ultrasound Subthalamotomy at an Early Stage · NA · completed
NCT04525638 — A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06607692 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación de investigación HM
Last refreshed: 2 June 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06607692.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing